B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels

Rheumatology (United Kingdom)

Volumn 51, Issue 7, 2012, Pages 1208-1215

  Lazarus, Mark N ^a   Turner Stokes, Tabitha ^a   Chavele, Konstantia Maria ^a   Isenberg, David A ^a   Ehrenstein, Michael R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Anti DNA antibodies; CD20 antibody; Rituximab; Systemic lupus erythematosus

Indexed keywords

DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN D; METHYLPREDNISOLONE; RITUXIMAB;

ADOLESCENT; ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL COUNT; CHILD; CONTROLLED STUDY; DISEASE ACTIVITY; DNA BINDING; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RELAPSE; REMISSION; SCHOOL CHILD; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES; CHILD; ENDOPEPTIDASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PHENOTYPE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863845120     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker526     Document Type: Article

References (29)

1. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929-39.
2. Lu TY, Ng KP, Cambridge G et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009;61:482-7.
3. Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9.
4. Terrier B, Amoura Z, Ravaud P et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010;62:2458-66.
5. Favas C, Isenberg DA. B-cell-depletion therapy in SLE-what are the current prospects for its acceptance? Nat Rev Rheumatol 2009;5:711-6.
6. Ehrenstein MR, Katz DR, Griffiths MH et al. Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int 1995;48:705-11.
7. Bootsma H, Spronk PE, Ter Borg EJ et al. The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation. Ann Rheum Dis 1997;56:661-6.
8. Tseng CE, Buyon JP, Kim M et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:3623-32.
9. Leandro MJ, Cambridge G, Edwards JC et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 2005;44:1542-5.
10. Dorner T, Jacobi AM, Lee J et al. Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J Immunol Methods 2011;363:187-97.
11. Anolik JH, Barnard J, Owen T et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007;56:3044-56.
12. Anolik JH, Barnard J, Cappione A et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004;50: 3580-90.
13. Hochberg MC, Chang RW, Dwosh I et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
14. Hay EM, Bacon PA, Gordon C et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58.
15. Jacobi AM, Odendahl M, Reiter K et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003;48:1332-42.
16. Wei C, Anolik J, Cappione A et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 2007;178: 6624-33.
17. Jacobi AM, Reiter K, Mackay M et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 2008;58:1762-73.
18. Jacquot S, Kobata T, Iwata S et al. CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 signaling. J Immunol 1997;159:2652-7.
19. Chan OT, Hannum LG, Haberman AM et al. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999;189:1639-48.
20. Yan J, Harvey BP, Gee RJ et al. B cells drive early T cell autoimmunity in vivo prior to dendritic cell-mediated autoantigen presentation. J Immunol 2006;177:4481-7.
21. Scheinberg MA, Cathcart ES. B cell and T cell lymphopenia in systemic lupus erythematosus. Cell Immunol 1974;12:309-14.
22. Odendahl M, Jacobi A, Hansen A et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000;165:5970-9.
23. Alarcon-Segovia D, Llorente L, Ruiz-Arguelles A. The penetration of autoantibodies into cells may induce tolerance to self by apoptosis of autoreactive lymphocytes and cause autoimmune disease by dysregulation and/or cell damage. J Autoimmun 1996;9:295-300.
24. Winfield JB, Winchester RJ, Kunkel HG. Association of cold-reactive antilymphocyte antibodies with lymphopenia in systemic lupus erythematosus. Arthritis Rheum 1975; 18:587-94.
25. Vila LM, Molina MJ, Mayor AM et al. Clinical and prognostic value of autoantibodies in Puerto Ricans with systemic lupus erythematosus. Lupus 2006;15:892-8.
26. Yu HH, Wang LC, Lee JH et al. Lymphopenia is associated with neuropsychiatric manifestations and disease activity in paediatric systemic lupus erythematosus patients. Rheumatology 2007;46:1492-4.
27. Petri M, Stohl W, Chatham W et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008;58: 2453-9.
28. Cambridge G, Isenberg DA, Edwards JC et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008;67:1011-6.
29. Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 2006;15: 570-6.